Abstract
Flap endonuclease-I (FEN-1) is involved in DNA repair and considered to be a novel target for the development of anticancer agents. N-hydroxy urea derivatives have been reported as FEN-1 inhibitors. To derive in vitro and in silico correlation, we have performed 2D-quantitative structure activity relationship (QSAR) analysis and docking studies on these compounds. 2D-QSAR models were developed using multiple linear regression (MLR) analysis and cross-validation using leave one out (LOO) method. The best model displayed R2 of 0.806 and Q2 of 0.607. Docking study revealed key interactions with desired amino acids and compare well with the in vitro potency of the reported compounds. Both studies reveal a link between FEN-1 inhibition and physicochemical descriptors or interactions with amino acids in active site. The information generated is first of its kind and may be helpful in the design of novel FEN-1 inhibitors.
Keywords: Cancer, QSAR, docking, flap endonuclease-1, glide, FEN-1.
Current Computer-Aided Drug Design
Title:QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors
Volume: 11 Issue: 4
Author(s): Pankaj Wadhwa, Priti Jain and Hemant R. Jadhav
Affiliation:
Keywords: Cancer, QSAR, docking, flap endonuclease-1, glide, FEN-1.
Abstract: Flap endonuclease-I (FEN-1) is involved in DNA repair and considered to be a novel target for the development of anticancer agents. N-hydroxy urea derivatives have been reported as FEN-1 inhibitors. To derive in vitro and in silico correlation, we have performed 2D-quantitative structure activity relationship (QSAR) analysis and docking studies on these compounds. 2D-QSAR models were developed using multiple linear regression (MLR) analysis and cross-validation using leave one out (LOO) method. The best model displayed R2 of 0.806 and Q2 of 0.607. Docking study revealed key interactions with desired amino acids and compare well with the in vitro potency of the reported compounds. Both studies reveal a link between FEN-1 inhibition and physicochemical descriptors or interactions with amino acids in active site. The information generated is first of its kind and may be helpful in the design of novel FEN-1 inhibitors.
Export Options
About this article
Cite this article as:
Wadhwa Pankaj, Jain Priti and Jadhav R. Hemant, QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors, Current Computer-Aided Drug Design 2015; 11 (4) . https://dx.doi.org/10.2174/1573409912666151124233628
DOI https://dx.doi.org/10.2174/1573409912666151124233628 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
2´,3´-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication
Current HIV Research Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design Dietary Phytoestrogens: Neuroprotective Role in Parkinson’s Disease
Current Neurovascular Research The ARRONAX Project
Current Radiopharmaceuticals Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Reactive Oxygen Species, Redox Signaling and Neuroinflammation in Alzheimer's Disease: The NF-κB Connection
Current Topics in Medicinal Chemistry Role of Lipid Rafts/Caveolae in the Anticancer Effect of Endocannabinoids
Mini-Reviews in Medicinal Chemistry Regulation of Gait and Balance: The Underappreciated Role of Neuronal Nicotinic Receptor Agonists
Current Pharmaceutical Design 5-HT2C Receptor Agonists as Potential Drugs for the Treatment of Obesity
Current Topics in Medicinal Chemistry Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry mTOR Targeted Cancer Chemoprevention by Flavonoids
Current Medicinal Chemistry Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design EGF Receptor as a Drug Target in Arterial Hypertension
Mini-Reviews in Medicinal Chemistry Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Neuroprotective Role of Hypothermia in Hypoxic-ischemic Brain Injury: Combined Therapies using Estrogen
Current Neuropharmacology Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors
Current Chemical Biology Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry